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Abstract
Background: Small trials with short term follow up suggest pharmacists’ interventions targeted at healthcare professionals
can improve prescribing. In comparison with clinical guidance, contemporary statin prescribing is sub-optimal and
achievement of cholesterol targets falls short of accepted standards, for patients with atherosclerotic vascular disease who
are at highest absolute risk and who stand to obtain greatest benefit. We hypothesised that a pharmacist-led complex
intervention delivered to doctors and nurses in primary care, would improve statin prescribing and achievement of
cholesterol targets for incident and prevalent patients with vascular disease, beyond one year.
Methods: We allocated general practices to a 12-month Statin Outreach Support (SOS) intervention or usual care. SOS was
delivered by one of 11 pharmacists who had received additional training. SOS comprised academic detailing and practical
support to identify patients with vascular disease who were not prescribed a statin at optimal dose or did not have
cholesterol at target, followed by individualised recommendations for changes to management. The primary outcome was
the proportion of patients achieving cholesterol targets. Secondary outcomes were: the proportion of patients prescribed
simvastatin 40 mg with target cholesterol achieved; cholesterol levels; prescribing of simvastatin 40 mg; prescribing of any
statin and the proportion of patients with cholesterol tested. Outcomes were assessed after an average of 1.7 years (range
1.4–2.2 years), and practice level simvastatin 40 mg prescribing was assessed after 10 years.
Findings: We randomised 31 practices (72 General Practitioners (GPs), 40 nurses). Prior to randomisation a subset of eligible
patients were identified to characterise practices; 40% had cholesterol levels below the target threshold. Improvements in
data collection procedures allowed identification of all eligible patients (n = 7586) at follow up. Patients in practices
allocated to SOS were significantly more likely to have cholesterol at target (69.5% vs 63.5%; OR 1.11, CI 1.00–1.23; p = 0.043)
as a result of improved simvastatin prescribing. Subgroup analysis showed the primary outcome was achieved by prevalent
but not incident patients. Statistically significant improvements occurred in all secondary outcomes for prevalent patients
and all but one secondary outcome (the proportion of patients with cholesterol tested) for incident patients. SOS practices
prescribed more simvastatin 40 mg than usual care practices, up to 10 years later.
Interpretation: Through a combination of educational and organisational support, a general practice based pharmacist led
collaborative intervention can improve statin prescribing and achievement of cholesterol targets in a high-risk primary care
based population.
Trial Registration: International Standard Randomised Controlled Trials Register ISRCTN61233866
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Introduction
Pharmacists from across the world aim to improve prescribing
and patient outcomes directly by consulting with patients through
pharmacist-led medication review [1,2], or indirectly by delivering
educational prescribing support to healthcare professionals [3–6].
Collaborative care models involving pharmacists targeting primary
care physicians have existed for over 15 years [7,8], and systematic
reviews of randomised studies suggest a reduction in cardiovascu-
lar risk through pharmacist intervention at patient [9] and
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e113370
healthcare professional level [10]. However, trials involve few
participants or pharmacists, have shortcomings in design, inclusion
criteria limit generalisability, outcomes are confined to prescribing
change and follow up is limited to one year at most [11,12].
Increasing demands from an aging population with more long
term conditions and an ongoing need for quality improvement in
prescribing has intensified the need for better evidence of long
term effects of pharmacists’ expanded professional (clinical) roles
[1,4,13,14].
Landmark studies involving patients with established athero-
sclerotic disease show that statin prescribing, with or without
achievement of target cholesterol, reduces morbidity and mortality
[15,16]. The largest trial to date (the Heart Protection Study),
tested the effect of Simvastatin 40 mg on all cause mortality and
found a statistically significant reduction from 14.7% to 12.9% in
patients with the following conditions: Previous Myocardial
Infarction;
Pre- or post-Coronary Artery Bypass Graft; Pre- or post-
Angioplasty; Angina; Ischaemic Heart Disease; Angiographic
coronary artery disease; Ischaemic stroke or Transient Ischaemic
Attack; Peripheral Arterial Disease; diabetes aged $ 40 years and
those with treated hypertension aged at least 65 years [15]. Despite
the availability of guidance [17,18] and an understanding of how
to integrate evidence into practice [19], clinical practice lags
behind clinical trial evidence and more implementation research is
needed [20]. Identification of eligible patients, prescribing, dosing
and achievement of cholesterol goals all remain suboptimal or, at
best, highly variable, across healthcare systems [19–25]. Together,
this suggests there may be merit in an intervention combining
educational and organisational support, targeted at prescribers
and the processes used in primary care general practices to offer
statins and achieve cholesterol targets in patients at highest risk of
vascular events.
In the UK, patients with atherosclerotic vascular disease are
regarded as a priority for treatment with statins regardless of
baseline cholesterol levels [17,26]. In practice, audit standards
recommend target cholesterol levels of less than 5 mmol/l (or less
than 4.2 mmol/l for patients with a Coronary Artery Bypass
Graft) [26–28].
In a large-scale, cluster randomised controlled trial within the
National Health Service (NHS) in Scotland, we tested the
hypothesis that a multifaceted Statin Outreach Support (SOS)
intervention targeted at healthcare professionals, by general
practice-attached pharmacists promoting the uptake of Simvasta-
tin 40 mg and the prescribing of other statins for patients with
atherosclerotic vascular disease, improves attainment of cholester-
ol targets and statin prescribing.
Methods
Trial design is published [29] and consistent with Consolidated
Standards of Reporting Trials [30]. The protocol for this trial and
supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1. The study was
funded and sponsored by NHS Greater Glasgow and Clyde. The
study sponsor had no role in the study design, delivery, analyses or
preparation of the manuscript.
The study is registered, number ISRCTN61233866.
Ethics statement
The study was approved by Greater Glasgow Community/
Primary Care Local Research Ethics Committee. In accordance
with Ethical committee approval, informed, written consent was
required from each participating practice; individual patient
consent was not required.
Study design
Practices. All primary care practices (n = 238, population
962,106) in Greater Glasgow Health Board (GGHB) were eligible
to participate. Sixty nine were single handed (SH; with only one
General Practitioner (GP) and 169 were group (G; with more than
one GP) practices. On average, practices served approximately
4,250 patients and had three salaried GPs, two salaried nurses and
attached staff e.g. district nurses [31].
Forty nine practices (25 SH and 24 G) were randomly selected
and invited to participate. After a face-to-face meeting with the
principal investigator to explain study procedures, 31 (15 SH, 16
G) practices provided written informed consent [29].
Patients. Patient level inclusion criteria were similar but not
identical to the largest statin study to date (the Heart Protection
Study), published before the SOS trial commenced [15]. We
identified patients who had confirmed atherosclerotic vascular
disease (secondary prevention), on the basis of at least one of the
following diagnoses appearing in the form of a Read Code (the
hierarchical clinical coding system used in the UK) in the primary
care medical records which contain the complete set of patients’
health and prescribing information:
Previous Myocardial Infarction;
Pre- or post-Coronary Artery Bypass Graft;
Pre- or post-Angioplasty;
Angina;
Ischaemic Heart Disease;
Angiographic coronary artery disease;
Ischaemic stroke or Transient Ischaemic Attack;
Peripheral Arterial Disease;
Patients with diabetes aged $ 40 years.
Patients with these diagnoses were included because they
formed part of the inclusion criteria for the Heart Protection Study
(which showed the benefits of simvastatin 40 mg) [15] and they are
regarded as a priority group in clinical guidelines and practice
[17,26,28]. We chose not to include patients with treated
hypertension (if also male and aged at least 65 years) because
patients with this entry criteria alone constituted only 1% of
patients in HPS and Scottish National Health Service policy
assumes they would be identified and managed through routine
primary prevention activity and guidance.
We conducted two cross sectional surveys of patient level data:
one at baseline to characterise the practice populations, and the
other at follow up for collection of study outcomes. This approach
precluded individual patient follow up although it was possible, at
follow up, to identify which patients had been eligible at baseline
(prevalent) or newly diagnosed or registered with the practice since
randomisation (incident).
Baseline data collection. Baseline data were collected
before randomisation in each participating practice as described
previously [29], and as follows. Using computerised Read code
searches in each practice, we produced lists of eligible patients, to
minimise selection and observation bias. In 26 practices, each
eligible patient’s electronic and paper-based record was consulted
and in the remaining five, largest practices, because of time
constraints, every third patient’s record was accessed. Baseline
data was therefore collected on a subset of eligible patients rather
than all eligible patients. Patient level baseline data (File S1, Page
27) were collected in a cross-sectional sample of 4,040 patients’
records in all 31 participating general practices (clusters) at
baseline.
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We categorised recruited General Practices depending on
whether they were a Group practice (n = 16) with several GPs,
or a Single Handed practice (n = 15) with only one GP in the
practice. We then separated practices into two groups according to
whether they were G or SH.
Ordering. Within G or SH strata we ordered practices using
the following ratio, which was calculated from a summary of each
practice’s baseline data:
Number of patients with cholesterol in the target range/
Number of patients with vascular disease.
Within each stratum, we arranged practices in ascending order
of ratio (from lowest to highest) and numbered each practice
sequentially.
Pairing (matching). Ordered and numbered within SH and
G strata, we paired practices so that those with similar ratios were
matched. This generated eight pairs of G practices and six pairs of
SH practices with one triplet of SH practices (31 practices in total).
Randomisation. We then randomly allocated (using a table
of random numbers) one practice from each matched pair into the
SOS arm and the other practice into the usual care arm. In the
triplet, two practices were randomly allocated to the SOS arm and
one to usual care.
This type of matched cluster design (‘matched pair’ in which
one of two matched clusters in a stratum are randomly assigned to
each intervention) is frequently adopted in cluster randomised
trials [32]. The allocation was, therefore, based on clusters rather
than on individuals and the identity of all the practices was
concealed until after allocation to SOS intervention (described
below) or usual care.
SOS intervention. The intervention was delivered from
January through December 2004.
Pharmacists delivering the intervention. Eleven NHS
employee pharmacists received 41 contact hours of training (File
S1, page 5) focusing on academic detailing; therapeutics and
general practice call/recall procedures. Training was delivered by
Cardiologists, Practice Nurses, GPs, and the research team. None
of the pharmacists had previous experience delivering the
intervention. Seven pharmacists delivered the SOS intervention
to one practice each and four pharmacists were allocated two
practices each.
Content and delivery of the intervention. Pharmacists
worked one day per week in their allocated practice(s) for one year
[29]. Using patient-level and summary prescribing information,
pharmacists provided organisational support comprising identifi-
cation of patients with potential for statin initiation and
optimization, by screening medical records. Through discussion
with GPs and Nurses, they identified individuals’ barriers to
prescribing change e.g. scepticism about the strength of evidence
for initiating a statin. Pharmacists subsequently devised ways to
help GPs and Nurses overcome these barriers then provided
individualized support to enact plans. Pharmacists aimed to
improve practices’ patient call and recall by systematically
identifying and categorising all eligible patients in the disease
register according to what the practice needed to do for those
patients who were not prescribed simvastatin 40 mg (or another
Table 1. Baseline patient characteristics.
SOS (15 practices; n = 2373 patients) Usual Care (15 practices; n= 1667 patients) P-value
Age (years; mean (SD) 68.2 (12.1) 68.5 (12.0) 0.311
Sex, male 1207/2373 (52.9%) 890/1667 (53.4%) 0.192
Qualifying diagnosis (No (%) of patients with each disease)
Angina/Ischaemic Heart Disease 1170/2373 (49.3%) 674/1667 (40.4%) ,0.001
Diabetes Mellitus, age $45 years 825/2373 (34.8%) 647/1667 (38.8%) 0.342
Myocardial Infarction 495/2373 (20.8%) 355/1667 (21.2%) 0.332
Cerebrovascular event 334/2373 (14.1%) 236/1667 (14.1%) 0.112
Peripheral Vascular Disease 286/2373 (12.0%) 161/1667 (9.6%) 0.202
Transient Ischaemic Attack 223/2373 (9.4%) 121/1667 (7.2%) 0.162
Coronary Artery Bypass Graft 200/2373 (8.4%) 144/1667 (8.6%) 0.542
Angioplasty 104/2373 (4.4%) 67/1667 (4.0%) 0.672
Vascular co-morbidities (mean (SD) 1.53 (0.8) 1.44 (0.7) ,0.001
Vascular co-morbidities excepting angina 0.81 (0.7) 0.84 (0.7) 0.761
Statin prescribing and cholesterol
Cholesterol target achieved 878/1768 (49.7%) 680/1307 (52.0%) 0.482
Simvastatin 40 mg and target cholesterol achieved 91/2373 72/1667 0.432
Cholesterol level (mean, SD) 5.08 mmol/l (1.1 mmol/l) 5.01 mmol/l (1.1 mmol/l) 0.141
Prescribed Simvastatin 40 mg 211/2373 (8.9%) 157/1667 (9.4%) 0.892
Prescribed Simvastatin any dose 529/2373 (22.3%) 443/1667 (26.6%) 0.152
Prescribed any statin 917/2373 (38.6%) 738/1667 (44.3%) ,0.001
Cholesterol tested 1768/2373 (74.5%) 1307/1667 (78.4%) 0.012
Cholesterol level, all patients with a statin 4.79 mmol/l (1.2 mmol/l) 4.71 mmol/l (1.1 mmol/l) 0.201
Cholesterol level, all patients without a statin 5.11 mmol/l (1.1 mmol/l) 5.08 mmol/l (1.0 mmol/l) 0.821
Statin prescribed at optimal dose 520/2373 (21.9%) 408/1667 (24.5%) ,0.001
doi:10.1371/journal.pone.0113370.t001
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statin at sufficient dose, if that was the individual GP’s strong
preference (File S1, page 4, Table 1) or if recommended by local
guidance (File S1, Page 7). Using information from patients’
records and comparing with management as described in local
guidance, pharmacists prepared individualised, written, evidence
based recommendations for each patient and passed these to the
GP for consideration and implementation. Practices subsequently
contacted patients to advise of changes to their prescription and/
or invite for a cholesterol test. Pharmacists systematically followed
up each patient’s plan to maximise patient uptake and minimise
dropout.
Pharmacists also provided educational support. This comprised
three face-to-face, one-to-one meetings between pharmacist and
GP, and pharmacist and nurse, at four-month intervals. Pharma-
cists provided individualised, unbiased information (in response to
learning needs identified during the first face to face meeting)
about statins, statin trials, feedback on the practice’s progress with
offering a statin to eligible patients, and the cost effectiveness of
improving statin prescribing (File S1, page 3). Pharmacists
recommended the prescription of Simvastatin 40 mg (or other
statins, if indicated) for patients who were not receiving one, and
dose-intensification for patients who were prescribed a statin at a
sub-optimal dose. Practices were free to choose to prescribe a
statin other than simvastatin e.g. atorvastatin, pravastatin or
fluvastatin, but these choices were countered in the public interest,
by the pharmacist describing the lower cost of simvastatin and
greater weight of evidence. Evidence based statin prescribing and
dosing was encouraged through repetition and reinforcement of
key learning points.
These recommendations were given regardless of patients’
baseline cholesterol levels consistent with local guidance (File S1,
page 7), National guidance [17,18] and best available evidence
[15]. Pharmacists recommended no changes when patients were
prescribed Simvastatin at a dose of at least 40 mg and target
cholesterol was achieved. Local opinion leaders’ views were sought
for questions arising from discussions that could not be routinely
addressed (File S1, page 3) [69].
After working in the practice one day per week for a year,
delivering the intervention, Pharmacists left their respective
practices and were not replaced, until after follow-up data were
collected from the last practice in March 2007.
Usual care. Usual Care practices received no pharmacist
support during the study. All practices in the study area including
those participating, received a printed copy of local cholesterol/
statin guidelines (File S1, Figure 1) at randomisation.
Outcomes. The primary outcome was the proportion of
patients achieving the cholesterol target in the intervention group
compared with the usual care group. Cholesterol targets were total
cholesterol ,5 mmol/l (except in patients with prior Coronary
Artery Bypass Graft who were required to have cholesterol ,
4.2 mmol/l), in line with local (File S1, Figure 1) and United
Kingdom audit standards [26,34].
Secondary outcomes were: the proportion of patients prescribed
simvastatin 40 mg with target cholesterol achieved; cholesterol
levels; prescribing of simvastatin 40 mg; prescribing of any statin
and the proportion of patients with cholesterol tested.
Measurement of outcomes. Two independent researchers
who were blinded to treatment allocation, collected outcomes by
extracting relevant electronic data from eligible patients’ electronic
records in general practices (File S1, Page 29). Follow-up coincided
with financial incentivisation for general practices to create and
maintain accurate disease registers for patients with conditions
including coronary heart disease or diabetes [33] and therefore
data recording in practices’ computers had improved to the point
where some practices were paperless and others were paper-light.
Due to these improvements, at follow up, researchers were able to
collect more patient outcome data during each visit to a practice,
compared with baseline data collection. Follow up data were
therefore collected for all 7586 eligible patients’ records in 30
general practices (Fig. 1 Trial profile), rather than from a subset as
was the case at baseline. However, due to limited availability of
opportunities to access practice computers, simultaneous collection
of data from 30 general practices was not possible. Scheduling of
different time slots for practice visits by researchers, led to different
dates of follow up between pairs. Outcome data were collected for
all eligible patients in 30 general practices between 1.4 and 2.2
years (mean 1.7 years) after randomisation. Data collection within
each pair started in the same week, to ensure comparable follow
up duration within pairs (File S1, Page 8).
Follow up analyses compared data in SOS with Usual Care
practices. Monthly, practice level prescribing data is routinely
collated across Scottish practices by the Information Statistics
Division, Scotland and forwarded to local level for onward
dissemination to practices. Simvastatin 40 mg prescribing data
from participating practices were summarised from January 2003
through January 2013, to ascertain any long term intervention
effects.
Sample size. Pilot work in five practices during 2002 found
50% of patients to have cholesterol targets achieved with an
intraclass correlation coefficient (ICC) of 0.4. Ninety percent had
cholesterol at target after the intervention. Pilot practices did not
take part in the main study. Assuming that data for 40 patients per
practice would be collected, we estimated that approximately 20
practices (10 per group) would be required to have 80% power,
allowing for the cluster randomisation, to detect an increase in the
proportion of patients with cholesterol at target to 90% in
intervention practices.
Statistical analyses. Analysis was by intention to treat.
Descriptive statistics for continuous variables are presented as
mean and standard deviation, and for categorical variables as
percentages. Due to the non-normal distribution of cholesterol
levels, a log-transformation was applied; therefore geometric
means describe cholesterol level outcome measures. The logged
values for this measure are used for all analyses. Linear and logistic
regression models were used to test for differences in the primary
and secondary outcomes between SOS and Usual Care groups for
continuous and binary outcomes respectively. Fixed effects models
were adjusted for practice pair as a covariate to account for the
matching at randomisation. Results are presented as intervention
effect or odds ratio (OR), 95% confidence interval (CI) and p-
value. Secondary analyses investigated the sensitivity of the results
to adjustments for age and sex. ICCs are presented for all
outcomes. A sensitivity analysis was carried out for the primary
outcome, adjusting for any statin prescribing at follow up, to assess
whether the treatment effect could be explained by increased statin
prescribing.
Subgroup analyses were carried out according to the following
variables: age; gender; practice-level socioeconomic deprivation;
practice type (SH/G); patient type (prevalent or incident); number
of co-morbidities (one vs. $2); ischaemic heart disease (IHD)
comorbidity; statin prescribed/not prescribed and cholesterol at
target or not, at baseline. Note that these baseline characteristics
were defined by data collected at follow-up, since data collected
before randomisation could not be linked to data collected at
follow-up because matching required each patient’s Community
Health Index number (CHI) and these were not collected at
baseline. Subgroup analyses were performed by adding subgroup
and the interaction between subgroup and treatment to the models
Pharmacist-Led Statin Prescribing Support
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described above. Results are presented graphically as the
treatment effect (and corresponding 95% confidence interval) for
each subgroup; the p-value for the interaction term is also
presented.
We consider p-values less than 0.05 to be statistically significant.
Data was managed and stored in the Robertson Centre for
Biostatistics (RCB), which is part of the Glasgow Clinical Trials
Unit and remains on the secure RCB network. Summarised data
are available through the principal investigator. All analysis was
carried out using SAS v9.1 for Windows (SAS Institute Inc, Cary,
North Carolina, USA).
Results
Recruitment secured the participation of 31 practices repre-
senting 12% (116,558) of the Greater Glasgow Health Board
population. Sixteen practices (8 Group practices and 8 Single
Handed practices) comprising 37 GPs and 20 nurses (19.5 whole
time equivalents) were allocated to SOS. Fifteen practices (8
Group practices and 7 Single handed practices) comprising
35 GPs and 18 nurses were allocated to Usual Care. Figure 1
Trial profile, illustrates the flow of practices through the study.
One SH practice had disbanded prior to randomisation, unknown
to investigators at the time, leaving 15 practices allocated to the
SOS arm. Of these 15 practices, 14 received the intervention.
Figure 1. Trial profile.
doi:10.1371/journal.pone.0113370.g001
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We included all 31 practices in baseline analyses. Follow up
analyses did not include the practice that had disbanded, leaving
30 practices. Practice level characteristics were comparable at
baseline [29].
There were some differences at baseline between patients in
SOS and patients in Usual care practices (Table 1). These
differences were in the proportions of patients with Angina/
Ischaemic Heart Disease; mean number of vascular co-morbid-
ities; prescribing of any statin and optimal dose statin. The
direction of the differences suggested it might be more difficult for
the intervention to have an effect e.g. fewer patients in SOS
practices were prescribed any statin and had their statin at optimal
dose at baseline. One SH practice withdrew after the first meeting,
but remained in the study, for analysis according to the intention
to treat principle. The intervention was implemented as intended
in 14 practices. At follow up, in response to the introduction of
updated electronic patient records at the time of the new General
Medical Services contract [33] we obtained data for all eligible
patients (n = 7586) from all 30 participating practices: 4,234
patients were identified from 15 SOS practices and 3,352 patients
from 15 Usual Care practices.
Primary outcome
A greater proportion of patients in the SOS arm achieved
cholesterol targets (2942/4234; 69.5% vs. 2130/3352; 63.5%, OR
1.11, 95% CI [1.00, 1.23]; p = 0.043. Table 2). ICCs were similar
to those estimated from baseline data.
Sensitivity analysis
The treatment effect was null after adjusting for any statin
prescribing at follow-up (OR 1.00 [0.90, 1.11]; p= 0.89)
suggesting the improvement in attainment of cholesterol targets
in the SOS arm can be explained by the increase in statin
prescribing.
Secondary outcomes
All secondary outcomes were in favour of SOS. Simvastatin
40 mg prescribing was greater in SOS practices (2497/4234;
59.0%) than in usual care practices (1267/3352; 37.8%): OR 2.06
[1.87, 2.28]; p,0.001. Table 2). This SOS effect was statistically
significant despite an increase in simvastatin 40 mg prescribing in
Usual Care practices from 9.4% at baseline (Table 1) to 37.8% at
follow-up. In SOS practices, the corresponding increase was from
8.9% (Table 1) to 59.0%.
All intervention effects were robust to adjustment for age and
sex. Adjusting for practice level ratio and practice type, instead of
adjusting for pair as covariate, gave similar results.
As planned, we have presented results from fixed effects models
that do not explicitly account for the clustering of the data.
Random (mixed) effects results were calculated, and due to the
small amount of variation between practices, the results are similar
to those from the fixed effects models (File S1, Page 21).
Subgroup analysis
SOS practices performed better in most subgroups in relation to
the primary and secondary outcomes (File S1, Pages 10–15).
Prevalent and incident patients
At follow up, categorisation of patients as ‘incident’ or
‘prevalent’ enabled evaluation of any differential intervention
effects. The intervention improved all outcomes in prevalent
patients. The intervention appeared to be relatively less effective in
incident compared with prevalent patients. Compared with
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incident patients in usual care practices, the improvement in
prescribing and cholesterol for incident patients from SOS arm
practices reached statistical significance in relation to four
outcomes: prescribing of simvastatin 40 mg and target cholesterol
achieved; cholesterol level; simvastatin 40 mg prescribing and
prescribing of any statin. Incident patients in SOS arm practices
also fared better than incident comparators in usual care, for the
remaining two outcomes (cholesterol target achieved and choles-
terol tested) but the extent of these improvements did not reach
statistical significance (Table 3).
Variation in outcomes in SOS versus usual care
Across SOS practices, the percentage of patients with
Simvastatin 40 mg achieving cholesterol targets at follow up
ranged from 27.4% to 56.5% compared with 6.45 to 55.6% in
Usual Care practices. This finding of a smaller range of outcome
values in SOS practices was noted in all other outcomes (Table 4).
Long term follow up with routine data
Simvastatin 40 mg prescribing data (for all patients, with or
without atherosclerotic disease) was available for each practice on
a monthly basis from January 2003 to January 2013 (Figure 2
Long term Simvaststin 40 mg prescribing). Despite an upward
trend in prescribing during the intervention period, prescribing in
SOS practices is seen to increase on commencement of the
intervention, and the difference persisted up to 10 years later.
Interpretation
Pharmacists’ practice-level educational and organisational
intervention lowered the risk of atherosclerotic events by
increasing the proportion of patients achieving target cholesterol
levels, and improving statin prescribing. The intervention effect
persisted despite increases in statin prescribing during the study
period. Similar increases were noted in other healthcare systems
over the same period [24,66].
In considering whether statin prescribing improvements were
key to the primary outcome being favourable, we adjusted for
statin prescribing as a covariate at follow up. When we did this, the
treatment effect was neutralised, suggesting the difference
observed in the primary outcome was driven mainly by the
prescribing of statins. There are other plausible although less likely
explanations for the favourable primary outcome: practices in the
SOS arm may have responded more positively to the General
Medical Services (GMS) contract Quality and Outcomes Frame-
work which asked all practices to create a register of patients with
CHD, Stroke and Diabetes and manage patients’ cholesterol
without any influence from the pharmacist intervention [34]; or
patients in SOS practices may have developed improved statin
adherence during the study period.
The results show practices in the SOS arm had significantly
improved prescribing for incident patients, but not achievement of
cholesterol targets. Looking at the secondary outcomes, this could
be due to the lack of intervention effect on having cholesterol
tested, which may reflect the shorter time period that the
intervention could affect the management of the incident patients.
We randomly allocated practices to SOS or Usual Care while
maintaining blinding, to minimise the chance of performance and
detection bias. However, we could not ensure ‘quadruple blinding’
[77] because practices were notified of their allocation in writing.
Performance bias was therefore possible through usual care
practices trying harder to achieve the outcomes for which their
SOS group counterparts received support. Patients remained
blinded to allocation throughout the study, because there was no
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requirement for written consent at patient level and the
intervention was mediated through practices. The Hawthorne
effect was unavoidable for participating GPs and Nurses, as is the
case in all randomised controlled trials involving an educational
component that cannot be masked by design.
Patients in the SOS arm had lower cholesterol levels at follow
up, suggesting adherence to prescribing changes, despite a known
tendency for non-adherence in the first year of prescribing and
following dose-intensification [56,57]. In recommending Simvas-
tatin 40 mg for patients regardless of cholesterol levels, SOS
accommodates a ‘fire and forget’ management strategy for a fixed
dose, generically available statin [58]. We did not collect
information on clinical events in view of the established and
robust link between cholesterol lowering, simvastatin prescribing
and reduced vascular events [15,16]. However, the difference in
simvastatin 40 mg prescribing (59% SOS vs. 38% usual care
(Table 2) approximates to the number needed to treat for 5 years,
to prevent one vascular event [15].
Since this study concluded, multinational surveys have consis-
tently shown clinically important variations in patient identifica-
tion, prescribing, dosing and lack of attainment of cholesterol
targets [21–24,59]. In UK general practice, due to features of the
pay-for performance contract such as threshold targets (after
reaching upper payment thresholds for a defined proportion of the
eligible population, practices do not receive additional payments
for target achievement in additional patients) and exception
reporting (practices can except (exclude) patients from payment
denominators, due to a variety of reasons e.g. no response to
invitations to attend the practice) [27], uncertainty exists over
whether target cholesterol is achieved in approximately 20% of
eligible patients [60]. These features of the UK contract
underscore the need to develop and test collaborative interventions
aiming to increase the uptake of evidence based practice. As far as
we are aware, our results provide, for the first time, empirical
evidence of patient [9] or healthcare professional [10] level
pharmacist-led interventions generating improvements in disease
markers or prescribing for longer than one year [6,61–65].
Table 4. Range of primary and secondary outcomes.
Outcome
SOS (15 practices; n =4234 patients)
N (%; range){
Usual care (15 practices; n = 3352 patients)
N (%; range) {
Cholesterol target achieved 2942 (69.5%; 49.0–77.5%) 2130 (63.5%; 35.6–83.4%)
Simvastatin 40 mg and cholesterol target achieved 1898 (44.8%; 27.4–56.5%) 935 (27.9%; 6.4–55.6%)
Cholesterol level (mmol/l) 4.22 (4.03–4.49) 4.36 (3.82–4.95)
Prescribed simvastatin 40 mg 2497 (59.0%; 30.7–71.8%) 1267 (37.8%; 15.2–65.7%)
Prescribed any statin 3682 (87.0%; 68.0–93.7%) 2509 (74.9%; 47.1–93.8%)
Cholesterol tested 3892 (91.9%; 73.3–98.8%) 2945 (87.9%; 65.8–97.4%)
{Cholesterol level given as geometric mean (range) mmol/l.
doi:10.1371/journal.pone.0113370.t004
Figure 2. Long term Simvastatin 40 mg prescribing in Intervention vs. Usual Care practices.
doi:10.1371/journal.pone.0113370.g002
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Differences between SOS study and other work
Previous work has shown pharmacists’ patient facing interven-
tions are capable of lowering cholesterol levels [66,70,71] or
improving the prescription of lipid lowering medicines [72] but we
are not aware of reports of improved surrogate clinical outcomes
from pharmacist intervention targeted at general practitioners.
The number of patients included was larger than previous
pharmacy led intervention studies. Follow up was longer than in
previous studies of this kind [11,12] which gives some assurance
that changes made in the study, had a lasting effect although
incident patients in SOS practices did not fare any better than
those in usual care practices in relation to the primary outcome.
Measuring outcomes over the long term is important for patients
with vascular disease because clinical benefits from statin use are
accrued over the long term [15,73]. As far as we are aware, follow
up in previous educational outreach type research was up to 12
months [72,74] and there are no previous reports of an effect
possibly lasting up to 10 years (Figure 2).
Strengths
The size of the treatment effect in previous studies involving
pharmacists delivering academic detailing/educational outreach
type interventions are generally lower than our finding
[1,3,5,11,35,36]. SOS may have had positive outcomes because
of the relatively narrow focus on statins (Simvastatin 40 mg in
particular) and cholesterol management for patients with vascular
disease that enabled GPs and the practice team to identify and
follow up a defined group of patients with a specific intervention.
Other investigators have delivered a broader spectrum of
educational messages with mixed success e.g. hypertension [37];
antibiotic prescribing for acute conditions [38–43]; multiple
prescribing topics [6]; and potentially inappropriate prescriptions
[44].
Prolonged contact time and regular, repeated visits enabled
pharmacists to develop working relationships with practice staff,
understand individual GP, Nurse and practice’s needs and then
provide individual educational and organisational support accord-
ingly. Tailored interventions are thought to be powerful predictors
of effectiveness [45,46], and fewer contacts are thought to predict
lower levels of success [47]. Key educational messages were
repeated and pharmacists facilitated change whenever this was
possible. These features of the SOS intervention can be aligned to
markers of quality in patient education interventions [48]. The
combination of organisational and educational support is likely to
have been synergistic. Organisational support included providing
practices with a list of recommendations for each patient who was
found to be sub-optimally managed, an approach previously found
to be successful [49,50] while others have cited an inability to
address organisational barriers as one reason for a neutral result
[51]. Collaboration and repeated intensive support to identify and
follow up eligible patients, together with timely communication,
are also likely to have been important features [8,10]. SOS
intervention comprised weekly visits to practices over one year,
which exceeds the number of contacts studied previously.
Soumerai observed an approximate doubling of the magnitude
of changes to targeted medicines when the number of visits
doubled [52] while others have suggested a minimum of three
visits to enable change to occur [53]. The Cochrane collaboration
considered the impact of the number of visits on the success of
academic detailing and found a wide range, from once weekly for
seven months [54] to single visits [55] with examples of successful
and unsuccessful outcomes across the spectrum [3].
The intervention was delivered as planned and effects lasted
longer than those seen in previous pharmacist led educational
intervention trials [4], and case management approaches [66].
SOS was delivered by pharmacists who had minimal additional
training. Participating practices were representative of practices in
the largest Health Board area in Scotland [29]. More pharmacists
delivered the intervention than in previous educational outreach
or organisational level interventions targeting cardiovascular
disease management. Data were collected from a greater number
of patients than in any previous complex intervention trial
involving pharmacists and prescribing [3,5,11,35]. The clinical
profiles of eligible patients were similar to participants in landmark
statin trials and surveys (File S1, Pages 23 and 24). Optimal dose
statin initiation and cholesterol lowering are of proven benefit for
patients with established vascular disease [15,16]. Sub-optimal
management of cholesterol and sub-optimal statin prescribing are
common [67,68] and the SOS intervention may offer a means of
addressing this public health need. In contrast with previous
pharmacist led trials [2,6,35,66], we did not select practices on the
basis of their capacity to benefit from the intervention, or only
include patients who had capacity to benefit, in our denominators.
By randomly selecting practices for inclusion in the trial, we
recruited a representative sample from Scotland’s largest health
board, and a large patient cohort to maximise transferability.
Together, these features support implementation in healthcare
systems with sub-optimal statin prescribing and cholesterol
management [19–25].
The SOS effect appears to be greater in practices where
baseline levels of statin prescribing and cholesterol target
achievement were lowest (File S1, Pages 15–20). The intervention
supported the least well-performing practices to achieve a higher
level of performance but did not boost performance of the top
practices beyond what they could achieve without the interven-
tion. In addition, variation in outcomes was minimised at follow
up in SOS practices compared to usual care (File S1, Pages 15–
20). This result may be due to the systematic approach to call and
recall introduced by pharmacists, ensuring all patients were
contacted by their practice on several occasions, by letter, phone
or opportunistically and offered a statin or cholesterol test. In this
respect, because of the additional time spent working through lists
of patients, the pharmacists may have enabled practices to reach
patients who had previously not responded to written invitations.
SOS may be more appropriately used in practices with outlying
(low levels) of statin prescribing and cholesterol target achieve-
ment. Because of the volume of work involved, usual care practices
were unlikely to have had the time to adopt this approach, and the
GMS contract does not incentivise the additional work involved in
persistently following up patients to increase uptake of statins or
other interventions among patients who do not respond to initial
invitations [34,60].
Limitations
The directions of baseline imbalances in two variables which
were related to the outcome (a reduced proportion of SOS arm
patients prescribed a statin and a reduced proportion prescribed
an optimal dose) are likely to have led to there being a greater
burden of work for pharmacists and practices in the SOS arm than
for practices in the Usual Care arm. The additional work comes
from there being proportionately more patients requiring changes
to their statin prescribing and cholesterol management, for tasks
such as patient identification, engagement and appointment
booking, prescribing, test ordering and booking follow up
appointments. Pharmacists supported practices to carry out all of
these tasks, and as SOS practices had a proportionately greater
burden at baseline, additional work was required to overcome the
burden. If practices were balanced at baseline in relation to these
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variables, the pharmacists would have had less of these tasks to
address, and more time to focus on other tasks e.g. providing
relevant educational support to GPs.
The clinical significance of the finding that achievement of
cholesterol targets was not statistically significantly greater in
incident SOS practices is unclear, given that cholesterol lowering
may not form a necessary part of the causal chain between statin
prescribing, consumption and improved clinical outcomes [15,58].
However, recent UK consensus recommendations suggest statins
should be prescribed to achieve values of at least ,2.5 mmol/l for
non HDL cholesterol [78]. Any improvement in clinical outcomes
resulting from this study are likely to be conditional on improved
statin prescribing persisting in both prevalent and incident patients
over the long term.
Baseline cholesterol data was only collected for a sample of the
prevalent patients at this time. The method of data collection did
not allow for linkage to follow-up data, therefore we did not have
baseline cholesterol levels for all prevalent patients identified at
follow-up.
As with other trials of complex, multifaceted interventions, the
effective components remain unknown without testing each
component individually [35,75].
Due to improvements in statin prescribing since the study
completed, if implemented today, to retain effect size, the
intervention may need to be targeted at underperforming practices
rather than a random selection.
We did not conduct an economic analysis and therefore the
policy cost-effectiveness of the SOS intervention remains un-
known. The cost of delivering the intervention over a single year
could be weighed against any longer term washover effect on statin
prescribing, and a comparison made with usual care (in the UK)
where general practices are financially incentivised annually for
continuing to achieve targets for prevalent and incident patients.
Previous economic analyses of pharmacist led outreach interven-
tions have shown mixed results [6,76].
By design, we did not track individual patients from baseline to
follow up, which precluded interpretation of results relative to pre-
intervention characteristics in the same patients. Follow up
analysis did not adjust for baseline differences however, these
were in a direction that acted against the intervention effect, and
so would not be expected to change findings. Improved
achievement of cholesterol targets at follow up in the intervention
group may have resulted from a combination of patients becoming
more adherent with their statins and more patients receiving
statins and retaining the same level of adherence. A greater
proportion of SOS group patients were prescribed optimal dose
statins, which suggests the latter, but we did not capture data on
adherence which limits interpretation of the impact of the
intervention on patients’ behaviour.
It is possible that other healthcare professionals could deliver
SOS, and the model could generate improved outcomes in other
therapeutic areas, but these hypotheses require further testing. The
possibility of a null effect in the primary outcome cannot be
ignored because of the narrow difference between the observed p-
value and the a-priori threshold value of 0.05, and because the
lower limit of the confidence interval included 1.00. However, all
other outcomes were statistically significantly different and in a
direction which favours the intervention. In particular, cholesterol
levels were reduced in the SOS group, indicating some degree of
change in practice by patients.
In 2004, coinciding with the study commencing, UK general
practitioners’ national contract was revised to financially incenti-
vise attainment of evidence based clinical quality indicators
including statin prescribing and cholesterol targets [33]. While
this raised practices’ awareness of the need to address this area, the
effect applied equally to all participating practices. Outcomes
remained statistically significant despite confounding introduced
by the UK pay-for-performance contract.
Conclusions
Given the challenges of an ageing population with multiple long
term conditions and sub-optimal prescribing, healthcare providers
require effective approaches to improve prescribing and thera-
peutic targets that are effective over the long-term. Morbidity and
mortality from cardiovascular disease remains high, and statin
prescribing remains sub-optimal. SOS offers a pragmatic model
for improving long term evidence-based statin prescribing, and
attainment of cholesterol targets, in a high risk population.
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